Education
About Us
Working with TipRanks
Follow Us
GeoVax Labs (GOVX)
NASDAQ:GOVX
GOVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.43 - $6.50
Previous CloseN/A
Volume281.82K
Average Volume (3M)1.20M
Market Cap
$19.85M
Enterprise Value$10.20M
Total Cash (Recent Filing)$3.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.85
Next Earnings
Nov 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding25,359,592
10 Day Avg. Volume904,050
30 Day Avg. Volume1,197,302
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue1.66
Enterprise Value/Gross Profit1.67
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$10.83Price Target Upside1325.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical StudiesAdditional data announcements from clinical studies with 04S1 could be positive catalysts through 2025.
Comparative AnalysisDSMB Review Suggests GEO-CM04S1 May Be Superior to mRNA Vaccine.
Vaccine DevelopmentGEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.
Bears Say
Contract TerminationTermination of the contract will not have a long-term material effect.
Project TerminationGeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.
GeoVax Labs News
GOVX FAQ
What was GeoVax Labs’s price range in the past 12 months?
GeoVax Labs lowest stock price was $0.43 and its highest was $6.50 in the past 12 months.
What is GeoVax Labs’s market cap?
GeoVax Labs’s market cap is $19.85M.
When is GeoVax Labs’s upcoming earnings report date?
GeoVax Labs’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.
How were GeoVax Labs’s earnings last quarter?
GeoVax Labs released its earnings results on Aug 06, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.348 by -$0.002.
Is GeoVax Labs overvalued?
According to Wall Street analysts GeoVax Labs’s price is currently Undervalued.
Does GeoVax Labs pay dividends?
GeoVax Labs does not currently pay dividends.
What is GeoVax Labs’s EPS estimate?
GeoVax Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GeoVax Labs have?
GeoVax Labs has 25,359,592 shares outstanding.
What happened to GeoVax Labs’s price movement after its last earnings report?
GeoVax Labs reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.348. Following the earnings report the stock price went down -9.589%.
Which hedge fund is a major shareholder of GeoVax Labs?
Currently, no hedge funds are holding shares in GOVX
Company Description
GeoVax Labs
GeoVax Labs (GOVX) is a biotechnology company specializing in developing human vaccines. The company's primary focus is on creating vaccines for infectious diseases, cancer immunotherapy, and other novel treatments by utilizing their innovative MVA-VLP vaccine platform. GeoVax leverages its expertise in vaccine development to address global health challenges, aiming to provide solutions for diseases such as HIV, Zika, Lassa fever, Ebola, and COVID-19.
GOVX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in revenue growth, regulatory advancements for GEO-MVA, and successful fundraising efforts. However, challenges such as the termination of the BARDA contract, increased expenses, and delays in clinical trials were also noted.View all GOVX earnings summariesGOVX Stock 12 Month Forecast
Average Price Target
$10.83
▲(1325.00% Upside)
Technical Analysis
Phio Pharmaceuticals
―
Moleculin Biotech
―
ABVC BioPharma
―
Addex Therapeutics
―
Sensei Biotherapeutics
―
Ownership Overview
0.69% Insiders
0.80% Mutual Funds
0.04% Other Institutional Investors
98.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---